Editas Medicine Inc EDIT

Editas Medicine Inc. is an American clinical-stage biotechnology company specialising in gene editing technologies, with a focus on developing CRISPR medicines for people with serious diseases. Serving the US healthcare sector, the firm was founded in 2013 to engage in the discovery, development, manufacture, and commercialisation of transformative genomic medicines for a broad class of diseases. Editas Medicine is based in Cambridge, Massachusetts, and has a second facility in Boulder, Colorado.

The firm’s work includes developing both in vivo gene edited therapies, which are administered to patients and are capable of editing genes inside the body, and ex vivo gene edited cell medicines, where the process is carried out in cells outside the body, and those edited cells are then transferred into patients.

Gene editing technologies have the potential to help patients living with a range of diseases, but the company primarily focuses on three main therapeutic areas: ocular diseases, such as Usher syndrome 2A and retinitis pigmentosa; oncology, with a focus on solid tumours and blood cancers; and blood diseases such as sickle cell disease and beta-thalassemia. The firm has been listed on the NASDAQ since it went public in 2016 and trades under the ticker EDIT.

Monitor the EDIT share price by adding it to your eToro watchlist.